Prognostic factors and an innovative nomogram model for patients with hepatocellular carcinoma treated with postoperative adjuvant transarterial chemoembolization

References

• Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):1–12.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314.
   PubMedGoogle Scholar
• Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200–207.
   PubMed Web of Science ®Google Scholar
• Poon RTP. Prevention of recurrence after resection of hepatocellular carcinoma: a daunting challenge. Hepatology. 2011;54(3):757–759.
   PubMed Web of Science ®Google Scholar
• Du Z-G, Wei Y-G, Chen K-F, et al. Risk factors associated with early and late recurrence after curative resection of hepatocellular carcinoma: a single institution. Hepatobiliary Pancreat Dis Int. 2014;13(2):153–161.
   PubMed Web of Science ®Google Scholar
• Kanda T, Imazeki F, Wu S, et al. The assessment of serum hepatitis C virus RNA 12 weeks after the end of treatment using TaqMan polymerase chain reaction is less relevant than after 24 weeks for predicting sustained virological response. Hepatology. 2011;54(4):1482; author reply 1482–1483.
   PubMed Web of Science ®Google Scholar
• Gu J, Zhang X, Cui R, et al. Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol. 2019;31(7):836–844.
   PubMed Web of Science ®Google Scholar
• Tao X, Lai ECH, Min AR, et al. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: a non-randomized comparative study. Hepato-gastroenterology. 2012;59(116):1198.
   PubMedGoogle Scholar
• Jing JS, Kang W, Zhang CZ, et al. Postoperative adjuvant transcatheter arterial chemoembolization after R0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion. Ann Surg Oncol. 2015;23(4):1344–1351.
   PubMed Web of Science ®Google Scholar
• Tong Y, Li Z, Liang Y, et al. Postoperative adjuvant TACE for patients of hepatocellular carcinoma in AJCC stage I: friend or foe? a propensity score analysis. Oncotarget. 2017;8(16):26671–26678.
   PubMedGoogle Scholar
• Schwartz JD, Schwartz M, Mandeli J, et al. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol. 2002;3(10):593–603.
   PubMed Web of Science ®Google Scholar
• Jiang JH, Guo Z, Lu HF, et al. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis. World J Gastroenterol. 2015;21(15):4627–4634.
   PubMed Web of Science ®Google Scholar
• Zheng-Gang R, Zhi-Ying L, Jing-Lin X, et al. Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J Gastroenterol. 2004;19:27–30.
   Google Scholar
• Zhou J, Zheng W, Zhenggang R, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study. Clin Cancer Res. 2018;24(9):2074–2081.
   PubMed Web of Science ®Google Scholar
• Sun X, Kaufman PD. Ki-67: more than a proliferation marker. Chromosoma. 2018;127(2):175–186.
   PubMed Web of Science ®Google Scholar
• Sorbye SW, Kilvaer TK, Andrej V, et al. Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas. PLOS One. 2012;7(10):e47068.
   PubMed Web of Science ®Google Scholar
• Ciancio N, Galasso MG, Campisi R, et al. Prognostic value of p53 and Ki67 expression in fiberoptic bronchial biopsies of patients with non-small cell lung cancer. Multidiscip Respir Med. 2012;7(1):29.
   PubMedGoogle Scholar
• Tsai T-J, Chau G-Y, Lui W-Y, et al. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery. 2000;127(6):603–608.
   PubMed Web of Science ®Google Scholar
• Cho YB, Lee KU, Lee HW, et al. Outcomes of hepatic resection for a single large hepatocellular carcinoma. World J Surg. 2007;31(4):795–801.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Duda DG, Sahani DV, et al. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011;8(5):292–301.
   PubMed Web of Science ®Google Scholar
• Ya-Peng Q, Jian-Hong Z, Zhi-Yin L, et al. Adjuvant transarterial chemoembolization for patients with hepatocellular carcinoma involving microvascular invasion. Am J Surg. 2019;217(4):739–744.
   PubMed Web of Science ®Google Scholar
• Xing H, Zhang WG, Cescon M, et al. Defining and predicting early recurrence after liver resection of hepatocellular carcinoma: a multi-institutional study. HPB. 2020;22(5):677–689.
   PubMed Web of Science ®Google Scholar
• Huang L, Li J, Yan J, et al. Early recurrence after curative resection in oligonodular hepatocellular carcinoma. Hepato-gastroenterology. 2013;60(121):28–31.
   PubMedGoogle Scholar
• Lee HY, Rhim H, Lee MW, et al. Early diffuse recurrence of hepatocellular carcinoma after percutaneous radiofrequency ablation: analysis of risk factors. Eur Radiol. 2013;23(1):190–197.
   PubMed Web of Science ®Google Scholar
• Shimoda M, Tago K, Shiraki T, et al. Risk factors for early recurrence of single lesion hepatocellular carcinoma after curative resection. World J Surg. 2016;40(10):2466–2471.
   PubMed Web of Science ®Google Scholar
• Gao Q, Zhu H, Dong L, et al. Integrated proteogenomic characterization of HBV-Related hepatocellular carcinoma. Cell. 2019;179(5):1240.
   PubMed Web of Science ®Google Scholar
• Mrouj K, Andrés-Sánchez N, Dubra G, et al. Ki-67 regulates global gene expression and promotes sequential stages of carcinogenesis. Proc Natl Acad Sci USA. 2021;118(10):e2026507118.
   PubMed Web of Science ®Google Scholar
• Cidado J, Hong YW, Rosen DM, et al. Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget. 2016;7(5):6281–6293.
   PubMedGoogle Scholar
• Liu F, Guo X, Dong W, et al. Postoperative adjuvant TACE-associated nomogram for predicting the prognosis of resectable hepatocellular carcinoma with portal vein tumor thrombus after liver resection. Int J Biol Sci. 2020;16(16):3210–3220.
   PubMed Web of Science ®Google Scholar
• Liu S, Guo L, Li H, et al. Postoperative adjuvant trans-arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg Oncol. 2018;25(7):2098–2104.
   PubMed Web of Science ®Google Scholar
• Hu H, Han XK, Long XR, et al. Prognostic nomogram for post-surgical treatment with adjuvant TACE in hepatitis B virus-related hepatocellular carcinoma. Oncotarget. 2016;7(36):58302–58314.
   PubMedGoogle Scholar
• Hu S, Gan W, Qiao L, et al. A new prognostic algorithm predicting HCC recurrence in patients with Barcelona clinic liver cancer stage B who received PA-TACE. Front. Oncol. 2021;11:4214.
   Google Scholar
• Mao S, Shan Y, Yu X, et al. A new prognostic model predicting hepatocellular carcinoma early recurrence in patients with microvascular invasion who received postoperative adjuvant transcatheter arterial chemoembolization. Eur J Surg Oncol. 2023;49(1):129–136.
   PubMed Web of Science ®Google Scholar